Tarsus Pharmaceuticals

Developing innovative therapies for Demodex blepharitis and eye care

Tarsus Pharmaceuticals is dedicated to developing therapies for a range of diseases in need of better solutions. The company’s lead product TP-03 is a topical ophthalmic that targets an underlying cause of blepharitis and has the potential to be the first-ever drug treatment for this condition. Tarsus’ product pipeline includes additional indications in eye care and other areas of high unmet clinical need.

Year of Investment
2019
Strategy
Life Sciences
Location
Irvine, California